Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2015

01-12-2015 | Original Article

Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas

Authors: Channa R. Jayasekera, Ryan B. Perumpail, David T. Chao, Edward A. Pham, Avin Aggarwal, Robert J. Wong, Aijaz Ahmed

Published in: Digestive Diseases and Sciences | Issue 12/2015

Login to get access

Abstract

Background

Despite the availability of safe and effective direct-acting antiviral drugs (DAAs), the vast majority of patients with chronic hepatitis C (HCV) in the USA remain untreated, in part due to lack of access to specialist providers.

Aims

To determine the effectiveness of DAA-based treatment in medically underserved areas in California, in a healthcare model dependent on task-shifting—wherein a visiting hepatologist assesses patients for treatment eligibility, but subsequent routine follow-up evaluation of patients prescribed treatment is devolved to a part-time licensed vocational nurse under remote supervision of the hepatologist.

Methods

We retrospectively determined rates of sustained virologic response 12 weeks after treatment completion (SVR-12), adverse events, and treatment discontinuations in patients who received sofosbuvir-based DAA regimens between December 2013 and November 2014.

Results

Despite limited specialist provider involvement in medically underserved areas, all but two of 58 patients completed treatment, and 88 % of patients achieved the curative endpoint of undetectable HCV RNA 12 weeks after completing treatment (sustained virologic response, SVR-12). Almost 80 % of patients with cirrhosis and 85 % of patients with prior treatment experience achieved SVR-12.

Conclusions

Treatment effectiveness with sofosbuvir-based regimens in medically underserved areas utilizing task-shifting from a specialist to a mid-level provider is comparable to those achieved in pivotal clinical trials for these regimens, and to “real-world” experiences of tertiary care centers in the USA.
Literature
1.
go back to reference Hepatitis and Liver Cancer. A national strategy for prevention and control of hepatitis B and C. Washington, DC: Institute of Medicine; 2010. Hepatitis and Liver Cancer. A national strategy for prevention and control of hepatitis B and C. Washington, DC: Institute of Medicine; 2010.
2.
go back to reference Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 2014;160:293–300.PubMedCentralCrossRefPubMed Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus Infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann. Intern. Med. 2014;160:293–300.PubMedCentralCrossRefPubMed
3.
go back to reference Reau N. HCV testing and linkage to care: expanding access: HCV testing and linkage to care. Clin. Liver Dis. 2014;4:31–34.CrossRef Reau N. HCV testing and linkage to care: expanding access: HCV testing and linkage to care. Clin. Liver Dis. 2014;4:31–34.CrossRef
4.
go back to reference Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester. doi:10.1002/14651858.CD007331.pub3. Accessed 12 Dec 2014. Kredo T, Adeniyi FB, Bateganya M, Pienaar ED. Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester. doi:10.​1002/​14651858.​CD007331.​pub3. Accessed 12 Dec 2014.
6.
go back to reference Chirikov VV, Shaya FT, Howell CD. Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients. Hepatology. 2015;62:68–78.CrossRefPubMed Chirikov VV, Shaya FT, Howell CD. Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in Medicare patients. Hepatology. 2015;62:68–78.CrossRefPubMed
7.
go back to reference Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal. Wkly. Rep. 2015;64:453–458.PubMed Zibbell JE, Iqbal K, Patel RC, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ≤ 30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb. Mortal. Wkly. Rep. 2015;64:453–458.PubMed
8.
go back to reference Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.CrossRefPubMed Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750–1755.CrossRefPubMed
9.
go back to reference Yehia BR, Schranz AJ, Umscheid CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101554.PubMedCentralCrossRefPubMed Yehia BR, Schranz AJ, Umscheid CA, Lo Re V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS ONE. 2014;9:e101554.PubMedCentralCrossRefPubMed
10.
go back to reference Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 2015;162:397.PubMedCentralCrossRefPubMed Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann. Intern. Med. 2015;162:397.PubMedCentralCrossRefPubMed
11.
go back to reference Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C Virus. Ann. Intern. Med. 2015;162:407.CrossRefPubMed Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C Virus. Ann. Intern. Med. 2015;162:407.CrossRefPubMed
12.
go back to reference Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 2011;364:2199–2207.CrossRefPubMed Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N. Engl. J. Med. 2011;364:2199–2207.CrossRefPubMed
13.
go back to reference Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S. Impact of rural residence and health system structure on quality of liver care. PLoS ONE. 2013;8:e84826.PubMedCentralCrossRefPubMed Rongey C, Shen H, Hamilton N, Backus LI, Asch SM, Knight S. Impact of rural residence and health system structure on quality of liver care. PLoS ONE. 2013;8:e84826.PubMedCentralCrossRefPubMed
14.
go back to reference Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014;384:1756–1765.CrossRef Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. The Lancet. 2014;384:1756–1765.CrossRef
15.
go back to reference Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013;368:1878–1887.CrossRefPubMed Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 2013;368:1878–1887.CrossRefPubMed
16.
go back to reference Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014;370:1993–2001.CrossRefPubMed Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med. 2014;370:1993–2001.CrossRefPubMed
17.
go back to reference Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013;368:1867–1877.CrossRefPubMed Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 2013;368:1867–1877.CrossRefPubMed
18.
go back to reference Jensen DM, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort (HCV-TARGET). The Liver Meeting: American Association for the Study of Liver Diseases, Boston, MA. Abstract 45: 2014. Jensen DM, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: Real-world experience in a diverse, longitudinal observational cohort (HCV-TARGET). The Liver Meeting: American Association for the Study of Liver Diseases, Boston, MA. Abstract 45: 2014.
19.
go back to reference Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment. Pharmacol. Ther. 2015;42:559–573.CrossRefPubMed Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment. Pharmacol. Ther. 2015;42:559–573.CrossRefPubMed
Metadata
Title
Task-Shifting: An Approach to Decentralized Hepatitis C Treatment in Medically Underserved Areas
Authors
Channa R. Jayasekera
Ryan B. Perumpail
David T. Chao
Edward A. Pham
Avin Aggarwal
Robert J. Wong
Aijaz Ahmed
Publication date
01-12-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3911-6

Other articles of this Issue 12/2015

Digestive Diseases and Sciences 12/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.